New drug cocktail aims to tame rare bleeding disorder
NCT ID NCT07400250
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether combining orelabrutinib (a targeted drug) with romiplostim (a platelet booster) can improve platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to standard treatments. About 28 participants will receive the combo for 24 weeks, with follow-up to 56 weeks. The goal is to see if this approach leads to more stable platelet levels and longer remission without rescue therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Orelabrutinib (a targeted cancer drug) and romiplostim (a platelet-boosting drug)
- What this could lead to
- If successful, this combination could help ITP patients achieve stable platelet counts and possibly reduce or stop other treatments.
- What could go wrong
- This is a small, early-phase trial (28 people) with no results yet. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental injection aims to boost platelets in chronic blood disorder
- New combo therapy aims to boost platelets in immune disorder
- New hope for kids with ITP: drug combo aims to control bleeding
- Can a vitamin a drug boost platelets in Hard-to-Treat ITP?
- Real-World study to track Eltrombopag's effectiveness in ITP patients
- New pill could help adults with low platelet disorder